166827-53-8

The use of photodynamic therapy (PDT) against cancer has received increasing attention over recent years. However, the application of the currently approved photosensitizers (PSs) is limited by their poor aqueous solubility, aggregation, photobleaching an

The present invention relates to metal complexes bearing at least one (E-E')-4,4'- bisstyryl-2,2'-bipyridine ligand (LIG1) of the following formula (I): or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also relates to pharmaceutical compositions comprising these complexes and at least one pharmaceutically acceptable excipient. The present invention also relates to the use of compounds of formula (I) or pharmaceutical compositions comprising thereof as drug and as photosensitizer agent in photodynamic therapy. The present invention also relates to methods of preparation of said complexes.

During the last decades, photodynamic therapy (PDT), an approved medical technique, has received increasing attention to treat certain types of cancer. Despite recent improvements, the treatment of large tumors remains a major clinical challenge due to th

The present invention provides a dye-sensitized solar cell comprising: a first electrode; an optical absorbing layer formed on one surface of the first electrode, and including at least one of bipyridine ruthenium-based compounds represented by the chemical formula (1), chemical formula (2), and chemical formula (3) as a bipyridine ruthenium-based dye; a second electrode disposed to face the first electrode having the optical absorbing layer formed thereon; and an electrolyte layer formed between the first electrode and the second electrode.COPYRIGHT KIPO 2016

In this work we report the preparation of six new donor-metal-acceptor (D-M-A) type complexes of ruthenium(II) with the highly absorbing chromophoric ligand 4,4′-bis(2-(4-methoxyphenyl)styryl)-2,2′-bipyridine, (L-OCH3, donor moiety) and substituted polypyridinic ligands with electron acceptor character (NN-A). The NN-A studied ligands were pyrazino[2,3-f][1,10]phenanthroline (ppl), 11-R-dipyrido[2,3-a:2′,3′-c]phenazine (dppz-R; R is H, NO2, or CN) and 10,11-[1,4-naphtalenedione]dipyrido[3,2-a:2′,3′-c]phenazine (Aqphen). The complexes were characterized by IR, NMR, UV-Vis spectroscopy and cyclic voltammetry. The potential NLO response of the complexes was evaluated by solvatochromic studies. Although the communication between D and A exists, the effect of the change of the acceptor moiety on the properties of the complexes is small and the behavior of the complexes is governed mainly by the donor ligand. The Metal to Ligand Charge Transfer bands (MLCT) exhibited by all complexes in the visible region have dominant electronic density transfer character from the metal to the chromophoric L-OCH3 ligand. The hypsochromic shift of this low energy absorption band on going from a less polar (benzene) to a more polar solvent (acetonitrile) indicated that a redistribution of the electronic density among the metal and the donor ligand is observed. This behavior permits to predict a NLO response for these types of complexes. The combination of high molar absorptivity with intraligand charge transfer (ILCT) mixing into the MLCT bands are encouraging for the generation of new materials with interesting NLO properties.

Two novel heteroleptic sensitizers, Ru((4,4-dicarboxylic acid-2,2′-bipyridine)(4,4′-bis(p-hexyloxystyryl)-2,2-bipyridine) (NCS)2, and Ru((4,4-dicarboxylic acid-2,2′-bipyridine)(4, 4′-bis(p-methoxystyryl)-2,2′-bipyridine) (NCS)2, code